α-N-acetylgalactosaminidase Levels in Panic Disorder
Key facts
- Who runs it
- Elazığ Mental Health and Diseases Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 66 people enrolled
- Started
- 1 May 2025
- Ended
- 1 Aug 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- No intervention was assigned as part of the research protocol.
- Record updated
- 29 June 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Other criteria
- For Panic Disorder (PD) Group:; Inclusion Criteria:; Age ≥18 years and <65 years; Diagnosis of PD according to DSM-5-TR; Drug-naïve at baseline; Exclusion Criteria:; Age <18 years and >65 years; Any psychiatric diagnosis other than PD; Active alcohol or substance use disorder; Significant medical illness; Incomplete follow-up
- For Healthy Control (HC) Group:; Inclusion Criteria:; Age ≥18 years and <65 years; Exclusion Criteria:; Age <18 years and >65 years; Any psychiatric diagnosis; Active alcohol or substance use disorder; Significant medical illness
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective observational cohort study investigated serum α-N-acetylgalactosaminidase levels in drug-naïve patients with Panic Disorder (PD) at baseline and after six weeks of follow-up and compared them with healthy controls (HC). Associations between enzyme levels, symptom severity, and inflammatory markers were examined. The study aimed to evaluate whether α-N-acetylgalactosaminidase levels are associated with PD symptom severity and inflammatory parameters.
The 2 groups in the trial
- Panic Disorder (PD)
Drug-naïve adult participants (18-65 years) diagnosed with Panic Disorder according to DSM-5-TR criteria. Participants were evaluated at baseline and after 6 weeks of routine clinical treatment. No intervention was assigned by the study protocol. Blood samples were collected for measurement of serum α-N-acetylgalactosaminidase levels and inflammatory parameters. Clinical symptom severity was assessed using the DSM-5 Panic Disorder Scale (PDS).
Treatment: No intervention was assigned as part of the research protocol.
- Healthy Control (HC)
Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum α-N-acetylgalactosaminidase levels and complete blood count inflammatory markers.
Treatment: No intervention was assigned as part of the research protocol.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- α-N-acetylgalactosaminidase Levels in Panic Disorder: A Prospective Observational Cohort Study
- Record updated
- 29 June 2026